This Plain Language Summary of Publication article (PLSP) from Immunotherapy, highlights the results of the OAKS and DERBY studies, which tested pegcetacoplan, the first FDA-approved treatment for geographic atrophy (GA), a form of late-stage age-related macular degeneration (AMD) commonly affecting people over 50. Pegcetacoplan’s approval was based on these study findings and is covered by Medicare and most U.S. insurance plans.

Visit the site using this link to read the article.

This PLSP is based on an article called ‘Pegcetacoplan for the treatment of geographic atrophy secondary to age-related macular degeneration (OAKS and DERBY): two multicentre, randomised, double-masked, sham-controlled, phase 3 trials’ and was published in The Lancet.

Visit Lancet using the link to read the original article.